0 75

Cited 25 times in

Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin

Authors
 S. J. Kim  ;  J. H. Kim  ;  C. S. Ki  ;  Y. H. Ko  ;  J. S. Kim  ;  W. S. Kim 
Citation
 ANNALS OF ONCOLOGY, Vol.27(3) : 508-513, 2016 
Journal Title
 ANNALS OF ONCOLOGY 
ISSN
 0923-7534 
Issue Date
2016
MeSH
Antibiotics, Antineoplastic/adverse effects ; Antibiotics, Antineoplastic/therapeutic use* ; Cell Line, Tumor ; DNA, Viral/blood ; Depsipeptides/adverse effects* ; Depsipeptides/therapeutic use* ; Epstein-Barr Virus Infections/pathology ; Epstein-Barr Virus Infections/virology ; Female ; Herpesvirus 4, Human/drug effects* ; Histone Deacetylase Inhibitors/adverse effects* ; Histone Deacetylase Inhibitors/therapeutic use ; Humans ; Lymphoma, Extranodal NK-T-Cell/drug therapy* ; Male ; Middle Aged ; Pilot Projects ; Prospective Studies ; Virus Activation/drug effects*
Keywords
EBV reactivation ; extranodal NK/T-cell lymphoma ; romidepsin
Abstract
BACKGROUND: Romidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However, the efficacy and safety of romidepsin has never been studied in patients with relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (ENKTL). PATIENTS AND METHODS: We conducted an open-label, prospective pilot study to evaluate the efficacy and feasibility of romidepsin in the treatment of patients with ENKTL. The treatment was intravenous infusion of romidepsin (14 mg/m(2)) for 4 h on days 1, 8, and 15 of a 28-day cycle, and was repeated until disease progression or the occurrence of unacceptable toxicity. RESULTS: A total of five patients enrolled on to this pilot study. However, three patients developed fever and elevated liver enzyme and bilirubin levels immediately after their first administration of romidepsin. We suspected that these events were associated with Epstein-Barr virus (EBV) reactivation because of the rapidly elevated EBV DNA titers in blood from these patients. An in vitro study with the ENKTL cell line SNK-6 cells also showed that HDAC inhibitors including romidepsin increased the copy number of EBV DNA in a dose-dependent manner. These findings suggested that romidepsin-induced histone acetylation reversed the repressed state of the genes required for EBV reactivation and that romidepsin treatment may have caused EBV reactivation in EBV-infected tumor cells in ENKTL patients. Therefore, we discontinued the enrollment of patients into this pilot study. CONCLUSIONS: Our study suggests that the use of romidepsin may cause severe EBV reactivation in patients with ENKTL.
Full Text
https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv596
DOI
10.1093/annonc/mdv596
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152758
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse